This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. As described in our last report, human lysyl oxidase-like 2 protein (HLOXL2) has been implicated in the metastasis of breast cancer cells and in the deposition of large amounts of collagen fibers. We anticipate therapeutic agents against HLOXL2 will be useful in preventing cancer from spreading and will reduce the recurrence of cancer following surgical removal of breast tumors. In order to develop these drugs, it is important to understand the basic biochemical and physiological functions of HLOXL2 and closely related proteins. To date, few biochemical studies have been reported for HLOXL2. Because it is difficult to work on human proteins (i.e., limited amounts, availability, inability to conduct genetic experiments), we have chosen to work with the fruit fly Drosophila melanogaster proteins. The genome of the fruit fly has two genes (dloxl1 and dloxl2) that encode proteins very similar to HLOXL2.
We aim to characterize these fly proteins and use the results to understand the function of human LOXL2 and its role in cancer metastasis. Initially, we determined that the two genes are differentially expressed in different tissue at distinct developmental stages. dloxl1 is expressed robustly in prepupae while dloxl2 is only expressed in adult flies. Tissue specific analyses have been used to demonstrate that the expression of dloxl1 is confined to salivary glands. Surprisingly, we found that dloxl2 was expressed only in adult heads and not in the bodies. To determine the tissue specific expression of dloxl2 in adult heads, we isolated polyA mRNAs from eya2 (eye absent) mutant flies We could not detect dlox2 expression in the eya2 samples, strongly suggesting that dloxl2 is expressed in the eye. We have begun to produce polyclonal antibodies specific for each of the Drosophila LOXL proteins. We have been able to obtain an antibody against a DlOXL2 peptide in the LOX core domain. The antibody recognizes a ~52 kDa band from bacteria that express a GST-tagged DLOXL2 LOX core domain but not from bacteria expressing a similar GST fusion protein from DLOXL1. We are currently testing the antisera on blots of Drosophila tissues. In addition, we are in the process of generating antibodies specific for DLOXL1 using a GST fusion of the entire DLOXL1 coding sequence, because our attempts to use DLOXL1-specific peptides have thus far have not been successful. Our immediate plan is to focus on defining the subcellular localization of DLOXLs by in situ immunostaining, developing loss-of-function-flies that lack DOXL1 to understand the physiological importance of the gene and the biochemical characterization of the native DLOXLs.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR015563-07
Application #
7381088
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Project Start
2006-05-01
Project End
2007-04-30
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
7
Fiscal Year
2006
Total Cost
$158,399
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Subramanian, Chitra; Grogan, Patrick T; Opipari, Valerie P et al. (2018) Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-?B activation. Oncotarget 9:14509-14523
Ishiguro, Susumu; Kawabata, Atsushi; Zulbaran-Rojas, Alejandro et al. (2018) Co-treatment with a C1B5 peptide of protein kinase C? and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation. Biochem Biophys Res Commun 495:962-968
He, Chenchen; Duan, Shaofeng; Dong, Liang et al. (2017) Characterization of a novel p110?-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. Prostate 77:1187-1198
White, Peter T; Subramanian, Chitra; Zhu, Qing et al. (2016) Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery 159:142-51
Ohta, Naomi; Ishiguro, Susumu; Kawabata, Atsushi et al. (2015) Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes. PLoS One 10:e0123756
Li, Benyi; Thrasher, James Brantley; Terranova, Paul (2015) Glycogen synthase kinase-3: a potential preventive target for prostate cancer management. Urol Oncol 33:456-63
Ishiguro, Susumu; Yoshimura, Kiyoshi; Tsunedomi, Ryouichi et al. (2015) Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. Cancer Biol Ther 16:307-16
Grogan, Patrick T; Sarkaria, Jann N; Timmermann, Barbara N et al. (2014) Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs 32:604-17
Li, Benyi; Sun, Aijing; Jiang, Wencong et al. (2014) PI-3 kinase p110?: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol 2:188-98
Bibis, Stergios S; Dahlstrom, Kelly; Zhu, Tongtong et al. (2014) Characterization of Leishmania major phosphatidylethanolamine methyltransferases LmjPEM1 and LmjPEM2 and their inhibition by choline analogs. Mol Biochem Parasitol 196:90-9

Showing the most recent 10 out of 240 publications